CBDNewsBreaks Archive - Page 23 of 278

WednesdayOct 13, 2021 2:39 pm

CBDNewsBreaks – BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE:7BC) Leveraging State-of-the-Art Facilities, Expertise in Rapidly Growing Market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health and wellness beverage and natural products company, is in a position to leverage its state-of-the-art facilities and expertise to manufacture its own beverage product lines and to provide white-label solutions to a growing list of third-party companies. This comes as a recent Expert Market Research (“EMR”) report projects that North America is likely to be the fastest-growing and largest marketplace for cannabis beverages and that the global market will grow at a 48% CAGR in the next five years. Thus, BevCanna is ideally situated. A recent article reads, “The…

MondayOct 11, 2021 2:25 pm

CBDNewsBreaks – RYAH Group Inc. (CSE: RYAH) Providing Reliable, Consistent Dose Administration and Monitoring Devices

RYAH Group (CSE: RYAH), a connected device and big data and technology company, offers a suite of precision intake control and management devices that provide a practical way to execute volume control guidelines safely. In a company blog post, discussed in a recent article, RYAH noted that a global task force had created three separate dosing protocols: routine administration, conservative administration and rapid administration, with each designed to ease a patient treating chronic pain into medical cannabis and treatment with THC if needed. Such dosing guidelines are just half of the equation. The other half is the delivery mechanism, as…

FridayOct 08, 2021 11:38 am

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM) recently announced it had signed a definitive agreement to acquire 100% of BayMedica Inc., a U.S.-based private company specializing in the manufacture and commercialization of rare cannabinoids. InMed CEO Eric A. Adams described the acquisition as a transformative transaction for the company as it would give InMed a breadth of synthetic cannabinoid manufacturing capabilities. “BayMedica brings unparalleled cannabinoid manufacturing expertise in both chemical synthesis and biosynthesis together with industry veterans who have been pioneers in this space,” a recent article quotes Adams as saying. The article further notes that, once closed, the transaction will create a…

WednesdayOct 06, 2021 1:58 pm

CBDNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Achieves 13% QOQ Revenue Growth, Marks Remarkable Q2 2021

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) recently released its financial results for the second quarter of fiscal 2021. The company’s revenue was up 13% to $13.3 million, from $11.8 million in Q1 2021. In addition to a growth in revenue, RWB also received the Florida Department of Health, Office of Medical Marijuana Use approval; closed the acquisition of Acreage Florida; secured 20 double wide fully enclosed cultivation pods that will offer approximately 19,000 square feet of turn-key cultivation space; and completed the more comprehensive portion of Michigan’s two-step application process for medical marijuana licensing through its wholly…

TuesdayOct 05, 2021 2:54 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Releases Preliminary Results Showing HyGrO Technology Could Increase Longevity of Cut Flowers

Golden Triangle Ventures (OTC: GTVH) released the successful results of preliminary testing of its proprietary HyGrO hydrogen water technology and is looking forward to pursuing larger-scale studies. The company will work with commercial-scale flower products to further evaluate the efficacy of GTVH’s new process. The preliminary research, which lasted 21 days, was designed to assess whether hydrogen-infused water via the HyFrontier Technologies HyGrO system would increase the longevity of cut flowers, including stock roses, carnations and gladiolas. “Two vases were filled, one with regular tap water and one with HyGrO water. The water was never changed, and pictures were taken…

MondayOct 04, 2021 12:33 pm

CBDNewsBreaks – The Alkaline Water Company Inc.’s (NASDAQ: WTER) (CSE: WTER) Alkaline88(R) and A88CBD(TM) to Exhibit at 2021 NACS Show

The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER), the country’s largest independent alkaline water company, today announced that its subsidiaries, Alkaline88 and A88 Infused Products Inc., will be exhibitors at the 2021 NACS Show. The event is slated to take place from Oct. 6-8, 2021, at McCormick Place in Chicago, Illinois. According to the update, the A88CBD(TM) booth will be featuring the brand’s new line of six functional CBD waters powered by Vessl(R). “The 2021 NACS Show is a great opportunity for The Alkaline Water Company to showcase two strong brands. We’re looking forward to meeting buyers and sharing with them our Deliciously…

WednesdaySep 29, 2021 1:36 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Provides Improved Delivery for Wide Range of Product Formats

Lexaria Bioscience Corp. (NASDAQ: LEXX), an innovator of drug delivery methods, is improving the speed and efficiency of orally delivered fat-soluble active molecules and drugs with its patented technology. “DehydraTECH promotes a more effective, less expensive form of oral drug delivery evaluated thoroughly in vivo, in vitro and human clinical testing,” reads a recent article. “The DehydraTECH technology is suitable for use with a wide range of product formats. These include pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter (‘OTC’) capsules, pills, tablets, and oral suspensions. The technology was specifically designed for formulating and delivering lipophilic (fat-soluble) drugs and active ingredients…

MondaySep 27, 2021 1:10 pm

CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent…

MondaySep 27, 2021 12:55 pm

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Completes First Step in European Expansion Plan

Flora Growth Corp. (NASDAQ: FLGC) recently closed a €2 million investment in Hoshi International Inc., a fully integrated cannabis company, and uniquely positioned to become the leading provider of cannabis and derivative products for the budding European market. With the investment, Flora is set to capitalize on Hoshi’s strong European presence as well as leverage its technical know-how and understanding of its European market to not only expand its reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. A recent article reads, “Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to…

FridaySep 24, 2021 2:13 pm

CBDNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish,” reads a recent article. In addition to the antiviral program, Lexaria is also focused on another applied R&D program — hypertension. On July 29, it released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for…

News and publishing service for CBD related companies

Contact us: 512.354.7000

CannabisNewsBreaks